AOD-9604 in One North — Fat Loss Peptide Research Guide
AOD-9604 research guide for One North. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 in One North: Sourcing, Purity & Protocols
Most researchers trying to source AOD-9604 in One North soon discover that local retail options are essentially nonexistent. This matters because AOD-9604 quality ranges widely across the market — from analytically confirmed high-purity product to products with serious contamination — and the vendor determines everything about the product. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis documenting HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. What follows is a vendor evaluation and quality guide built specifically around AOD-9604, covering everything a One North researcher needs before placing a first order.
AOD-9604 Mechanisms Explained
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in One North studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Sourcing Research-Grade AOD-9604
Quality AOD-9604 sourcing begins with a useful first test: does this vendor make batch-matched COAs available before purchase? Those who make this data freely available are demonstrating research-grade standards. The HPLC analytical chromatogram is the most important document in the COA: it should show a large primary peak representing AOD-9604, with minimal secondary peaks representing impurities — purity should be stated as ≥98%. Community reputation in research forums is a valuable complement to COA verification — vendors with multi-year positive track records have built their reputation on real product performance. Hold lyophilised AOD-9604 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and return unused portion to the freezer.
Order AOD-9604 — ships to One North
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Proper handling of AOD-9604 requires strict sterile technique during reconstitution — alcohol-swabbed septum, fresh needles, clean working environment — and cold chain maintenance from receipt through use. The most significant preventable safety hazard in AOD-9604 research is endotoxin from inadequately tested product — a confirmed endotoxin test result in the lot-matched COA is the key safeguard. The research literature on AOD-9604 should be read critically before planning any study — study approaches, dose levels, and measured endpoints vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
